

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2016 Annual Meeting of Stockholders of Signal Genetics, Inc. (the “Company”), held on June 15, 2016, three proposals were submitted to and approved by the stockholders of the Company. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 9, 2016. The final results for the votes regarding each proposal are set forth below.

1. Stockholders elected five directors to the Company’s Board of Directors to hold office for a one-year term until the annual meeting of stockholders in 2017 and until their successors are elected and qualified. The votes regarding this proposal were as follows:

| | For | Against | Abstained |
|-------------------------|------------|----------------|------------------|
| Bennett S. LeBow | 4,298,612 | 340,259 | 10,200 |
| Samuel D. Riccitelli | 3,541,776 | 1,047,095 | 60,200 |
| David A. Gonyer, R. Ph. | 3,547,807 | 990,675 | 110,589 |
| Douglas A. Schuling | 3,550,276 | 987,306 | 111,489 |
| Robin L. Smith, M.D. | 3,533,671 | 1,000,442 | 114,958 |

2. Stockholders ratified the selection of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes regarding this proposal were as follows:

| For | Against | Abstained |
|------------|----------------|------------------|
| 6,893,644 | 1,238,328 | 145,177 |

3. Stockholders approved the Amendment to the Company’s Certificate of Incorporation Effecting a Reverse Stock Split of the Company’s Common Stock in accordance with a ratio to be determined by the Company’s Board of Directors within a range of one share of Common Stock for every two (2) to twenty (20) shares of Common Stock:

| For | Against | Abstained |
|------------|----------------|------------------|
| 6,470,138 | 1,721,729 | 85,282 |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGNAL GENETICS, INC.

By: /s/ Tamara A. Seymour
Name: Tamara A. Seymour
Title: Chief Financial Officer

Date: June 16, 2016